IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate the recommended dose for further clinical
development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics
and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with
advanced B cell non-Hodgkin lymphoma (NHL).